About Dipanjan Banchur
Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master’s degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets. His goal is to help investors make the best investment decisions based on a fundamental approach.
Recent Articles By Dipanjan Banchur
3 Trending Food Maker Stock Buys Showing Gains
As inflation continues its downward trend, food manufacturers will stand to benefit as food consumption is likely to grow. Moreover, population growth, the use of technology, expansion into newer markets, and changing consumer preferences are all expected to boost the industry’s prospects. Amid this backdrop, it could be wise to buy fundamentally strong food maker stocks John B. Sanfilippo & Son (JBSS), HF Foods (HFFG), and Ingredion (INGR). Read on...
3 Consumer Financial Stocks Worth Considering in 2024
Continued digitization of financial services and rising demand for personalized, efficient, convenient, and accessible financial services are boosting the consumer financial services sector’s prospects. Given this backdrop, it could be wise to invest in fundamentally strong consumer financial stocks PayPal (PYPL), AssetMark Financial Holdings (AMK), and EZCORP (EZPW). Keep reading…
Are These 3 Auto Stocks Targeting 2024 Gains?
The shift to electric vehicles, the use of advanced components, easing inflation, and the expected cut in interest rates are enhancing the growth outlook for the automotive industry. Therefore, lets analyze whether auto stocks Isuzu Motors (ISUZY), Garrett Motion (GTX), and Blue Bird (BLBD) are the right picks for 2024...
Is Limoneira Co (LMNR) a Buy or Sell Post-Earnings?
Agribusiness company Limoneira (LMNR) reported better-than-expected revenue during the fourth quarter, but its loss per share was higher than the consensus estimate. The company expects its margins to improve in fiscal 2024 due to its strategic initiatives. However, the stock trades at an expensive valuation. So, is the stock a buy or sell post-earnings? Read on to learn my view…
Unlocking Year-End Gains with 3 “Buy NOW” Tech Stocks
Digital transformation initiatives and the adoption of emerging technologies are setting up the tech industry for long-term growth. Therefore, it could be wise to buy fundamentally strong tech stocks Teradata (TDC), TTM Technologies (TTMI), and Ceragon (CRNT) for year-end gains. Read on...
How Much Momentum Is Left in These Promising Software Stocks?
Digital transformation initiatives, the shift to cloud-based solutions, and the adoption of emerging technologies like generative AI are expected to bolster the software industry’s growth. Therefore, it could be wise to take advantage of the momentum in fundamentally strong software stocks SAP SE (SAP), DocuSign (DOCU), and Sapiens International (SPNS). Let’s discuss…
4 Outsourcing Stocks With Year-End Potential
Enterprises are largely focusing on their core competencies, operational efficiency, cost savings, scalability, etc., leading to the expansion of the outsourcing industry. In this scenario, it could be wise to consider buying fundamentally strong outsourcing stocks Nomura Research Institute (NRILY), Stantec (STN), ManpowerGroup (MAN), and Hudson Global (HSON), given their solid potential. Read on...
NIKE (NKE) Earnings Preview: Athletic Stock Buy or Sell?
Sports apparel retailer NIKE (NKE) will report its second-quarter results on December 21. While its revenue is expected to rise, its EPS is expected to remain flat year-over-year. Additionally, it trades at an expensive valuation compared to its peers. Therefore, is the stock a buy or sell now? Let’s discuss…
Analyzing 3 Pharma Stocks for Year-End Gains?
The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read on...